The FDA has given its nod to the first glucose-monitoring app designed to be used with smartphones and other devices that can remotely track the health of a diabetic and "share" the information with up to 5 additional "followers."
Researchers at Curtin University's Biotechnology and Drug Development Research Laboratory in Perth, Australia, are developing a microcapsule formulation that they say improves the drug delivery and absorption of diabetes drugs.
The hepatitis C payer negotiations may be making the biggest headlines these days, but diabetes contracts were making headlines first. And if Eli Lilly & Co. and its drugs are any indication, those headlines are likely to continue.
DexCom is a medical device standout with its aggressive revenue growth profile at the JP Morgan Healthcare Conference in San Francisco, CA. It prereported upbeat fourth quarter and 2014 results with unaudited 2014 product revenues up a whopping 64% to $257 million from the prior year.
GlySens will use a $12 million Series C financing to conduct a clinical trial for a second iteration of its receiver and implantable sensor that enable continuous glucose monitoring for diabetic patients.
Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.
Bayer hopes to sell its ailing diabetes device unit to help bolster growth and fund a potential acquisition of Zoetis. The conglomerate would like to focus more closely on medicines, which has been a faster growth area than devices.
Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.
Sanofi said Tuesday that its diabetes sales would be flat for 2015, thanks to payer contracts. Lantus, the company's top-selling drug with more than $7 billion in 2013 sales, was able to win reimbursement in 90% of the U.S. market, CEO Chris Viehbacher--departed as of today--said during the third-quarter earnings call.